menu
    • menu
    [{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLP COVID-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyMD Pharmaceuticals \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Oramed Pharmaceuticals"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oravax Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyMD Pharmaceuticals \/ Oravax Medical","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Oravax Medical"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Bascom Palmer Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Bascom Palmer Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Bascom Palmer Eye Institute"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"MYMD-1","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MYMD-1","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MYMD-1","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol Analog","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"PharmaCyte Biotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ PharmaCyte Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ PharmaCyte Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by MyMD Pharmaceuticals

    Menu

    MyMD Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : PharmaCyte Biotech

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Makes $7 Million Investment in MyMD for Inflammatory Disease

                            Details : The financing aims to support MyMD in advancing its lead product MYMD-1 (isomyosamine), which is being evaluated in the mid-stage clinical trial studies for the treatment of sarcopenia.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : PharmaCyte Biotech

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

                            Details : MYMD-1 (isomyosamine), a next generation, oral selective inhibitor of tumor necrosis factor-alpha, a driver of chronic inflammation, being studied for rheumatoid arthritis.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 06, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol Analog

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBDâ„¢, Reduced Acute Inflam...

                            Details : Supera-CBDâ„¢ is a synthetic, non-toxic cannabidiol (CBD) analog that is an 8000-times more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures.

                            Brand Name : Supera-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2023

                            Lead Product(s) : Cannabidiol Analog

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Or...

                            Details : MYMD-1, a next generation, oral selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy ...

                            Details : MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated as therapy for delaying aging.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD...

                            Details : MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated for rheumatoid arthritis.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-Î...

                            Details : MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Katalyst Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MyMD Announces $15 Million Offering with Existing Investors

                            Details : The financing will support the continued development of MYMD-1 for sarcopenia, an aging indication. MYMD-1® regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 21, 2023

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Katalyst Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British ...

                            Details : MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            MyMD Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MyMD Pharmaceuticals Announces Publication of Phase 1 Data for Oral TNF-alpha Inhibitor MYMD-1® in Peer-Revie...

                            Details : MYMD-1 (isomyosamine) is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based autoimmune diseases are treated.

                            Brand Name : MYMD-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2022

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth